Lifeboat Foundation

I suggest two responses to this difficult challenge for the United States and its allies: At the time of attack, the allies should respond with nonnuclear retaliation as long as politically feasible, in order to prevent further nuclear escalation. However, this will be difficult given the likely post-strike panic and hysteria. So, in preparation, the US should deconcentrate its northeast Asian conventional footprint, to reduce North Korean opportunities to engage in nuclear blackmail regarding regional American clusters of military equipment and personnel, and to reduce potential US casualties and consequent massive retaliation pressures if North Korea does launch a nuclear attack.

North Korean first-use incentives. The incentives for North Korea to use nuclear weapons first in a major conflict are powerful:

Operationally, North Korea will likely have only a very short time window to use its weapons of mass destruction. The Americans will almost certainly try to immediately suppress Northern missiles. An imminent, massive US-South Korea disarming strike creates an extreme use-it-or-lose-it dilemma for Pyongyang. If Kim Jong-Un does not use his nuclear weapons at the start of hostilities, most will be destroyed a short time later by allied airpower, turning an inter-Korean conflict into a conventional war that the North will probably lose. Frighteningly, this may encourage Kim to also release his strategic nuclear weapons almost immediately after fighting begins.

Studies find a densely connected network of neurons that communicate over long distances, rather than across synapses.

Joining space technology and the automotive industry brings new economic and environmental benefits, but more investments and a faster pace are needed in Europe.

The question is not whether there will be a machine that can read your mind. Rather, it is when. Before that, governments across the world need to consider ‘neurorights’ to protect citizens’ brains against neurotechnology.

The second-and fourth-most distant galaxies ever observed have been discovered in a region of space known as Pandora’s Cluster, or Abell 2,744, using data from NASA’s James Webb Space Telescope (JWST). Following up on a deep field image of the area, an international team led by Penn State researchers confirmed the distance of these ancient galaxies and inferred their properties using new spectroscopic data — information about light emitted across the electromagnetic spectrum — from JWST. At nearly 33 billion light years away, these incredibly distant galaxies offer insights into how the earliest galaxies might have formed.

Unlike other galaxies confirmed at this distance that appear in images as red dots, the new galaxies are larger and appear like a peanut and a fluffy ball, according to the researchers. A paper describing the galaxies appears today (Nov 13) in the journal Astrophysical Journal Letters.

“Very little is known about the early universe, and the only way to learn about that time and to test our theories of early galaxy formation and growth is with these very distant galaxies,” said first-author Bingjie Wang, postdoctoral scholar in the Penn State Eberly College of Science and a member of the JWST UNCOVER (Ultradeep NIRSpec and NIRCam ObserVations before the Epoch of Reionization) team that conducted the research. “Prior to our analysis, we knew of only three galaxies confirmed at around this extreme distance. Studying these new galaxies and their properties has revealed the diversity of galaxies in the early universe and how much there is to be learned from them.”

While currently available PCSK9 inhibitor medications to lower cholesterol must be administered every few weeks by injection, a new, investigational PCSK9 inhibitor called recaticimab safely lowered bad cholesterol more than 50% when injected every 1–3 months, depending on dose.

A new PCSK9 inhibitor (recaticimab) injected every one to three months may work safely and provide more flexible dosing to lower cholesterol, according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2023. The meeting, Nov. 11–13, in Philadelphia, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.

“Previous studies found that 30% to 40% of people discontinued their current PCSK9 therapies, given every two to four weeks, during or after six months of beginning treatment. More flexible dosing with recaticimab, given up to every 12 weeks, might increase the proportion of people with high levels of bad cholesterol to stick with their recommended treatment to lower bad cholesterol levels and reduce risk of heart disease,” said lead study author Xin Du, Ph.D., a professor of cardiology at Beijing Anzhen Hospital and the Capital Medical University in Beijing, China.

Two Eötvös Loránd University researchers have made an exciting breakthrough in understanding how we age.

Researchers Dr. Ádám Sturm and Dr. Tibor Vellai from Eötvös Loránd University in Hungary have achieved a significant discovery in the study of aging. Their research centered on “transposable elements” (TEs) in our DNA

DNA, or deoxyribonucleic acid, is a molecule composed of two long strands of nucleotides that coil around each other to form a double helix. It is the hereditary material in humans and almost all other organisms that carries genetic instructions for development, functioning, growth, and reproduction. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

Contrary to the commonly-held view, the brain does not have the ability to rewire itself to compensate for the loss of sight, an amputation or stroke, for example, say scientists from the University of Cambridge and Johns Hopkins University.

Meta, the parent company of Facebook, has made a groundbreaking development in brain-computer interface technology. They have unveiled an AI system that can decode visual representations and even “hear” what someone is hearing by studying their brainwaves. These advancements in brain-machine interface technology have the potential to transform our relationship with artificial intelligence and its potential applications in healthcare, communication, and virtual reality.

The University of Texas at Austin has developed a new technology that can translate brain activity into written text without surgical implants. This breakthrough uses functional Magnetic Resonance Imaging (fMRI) scan data to reconstruct speech. An AI-based decoder then creates text based on the patterns of neuronal activity that correspond to the intended meaning. This new technology could help people who have lost the ability to speak due to conditions such as stroke or motor neuron disease.

Despite the fMRI having a time lag, which makes tracking brain activity in real-time challenging, the decoder was still able to achieve impressive accuracy. The University of Texas researchers faced challenges in dealing with the inherent “noisiness” of brain signals picked up by sensors, but by employing advanced technology and machine learning, they successfully aligned representations of speech and brain activity. The decoder works at the level of ideas and semantics, providing the gist of thoughts rather than an exact word-for-word translation. This study marks a significant advance in non-invasive brain decoding, showcasing the potential for future applications in neuroscience and communication.